capital partners news from FierceBiotech

Even before its first compound hits the clinic, Concert Pharmaceuticals is having no trouble raising venture funds. The Lexington, MA-based developer has just ginned $37 million in a new venture Read more...

Venture capitalists Rich Kollender and Steve Kraus are joining the board at Transave after helping come up with $35 million in new venture backing to get the developer through to proof-of-concept Read more...

California's stem cell institute says the property management company that promised to underwrite all their office operating costs in San Francisco appears to be reneging on the deal, and they're Read more...

The Dutch biotech PanGenetics has rounded up $34 million in venture backing for the clinical development of two antibody programs. The round was led by Edmond de Rothschild Investment Partners with Read more...

Denmark's Santaris Pharma has banked $30 million from its latest venture round. Gilde Healthcare Partners put up much of that money with BankInvest, Novo, LD, Forbion Capital Partners, Global Life Read more...

Paris-based Fovea Pharmaceuticals has raised €30 million ($44 million) in a Series B financing. The round was led by Forbion Capital Partners and also included Sofinnova Partners, Abingworth, Read more...

Genzyme is laying claim to the keys to Bioenvision after winning shareholders' approval of the $345 million buyout. SCO Capital Partners, which owns 13 percent of Bioenvision, had Read more...

Press Release: Kiadis Pharma Raises Euro 15 Million to Advance Oncology Pipeline

Read more...

FierceBiotech caught up with Bart Bergstein, the managing partner of Forbion Capital Partners, earlier this week to discuss the latest trends he's seeing in venture capital. Forbion operates from …

Read more...

Press Release: Forbion Capital Partners, Raises a EUR 200M Life Sciences Fund

Read more...